MX2022016574A - Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas. - Google Patents

Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas.

Info

Publication number
MX2022016574A
MX2022016574A MX2022016574A MX2022016574A MX2022016574A MX 2022016574 A MX2022016574 A MX 2022016574A MX 2022016574 A MX2022016574 A MX 2022016574A MX 2022016574 A MX2022016574 A MX 2022016574A MX 2022016574 A MX2022016574 A MX 2022016574A
Authority
MX
Mexico
Prior art keywords
immunogens
redesigned
soluble
coronavirus spike
protein immunogens
Prior art date
Application number
MX2022016574A
Other languages
English (en)
Inventor
Jiang Zhu
Linling He
Ian A Wilson
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of MX2022016574A publication Critical patent/MX2022016574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona inmunógenos derivados de proteína S de coronavirus solubles rediseñados que se estabilizan mediante modificaciones específicas en las secuencias S solubles tipo silvestre. En la invención también se proporcionan vacunas de nanopartículas que contienen los inmunógenos S solubles rediseñados mostrados en las nanopartículas de auto-montaje. Las secuencias de polinucleótidos que codifican para los inmunógenos rediseñados y las vacunas de nanopartículas también se proporcionan en la invención. La invención proporciona además métodos para usar las composiciones de vacuna en diferentes aplicaciones terapéuticas, por ejemplo, para prevenir o tratar infecciones coronavirales.
MX2022016574A 2020-06-29 2020-10-01 Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas. MX2022016574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063045557P 2020-06-29 2020-06-29
US17/019,825 US10906944B2 (en) 2020-06-29 2020-09-14 Stabilized coronavirus spike (S) protein immunogens and related vaccines
PCT/US2020/053714 WO2022005503A1 (en) 2020-06-29 2020-10-01 Stabilized coronavirus spike (s) protein immunogens and related vaccines

Publications (1)

Publication Number Publication Date
MX2022016574A true MX2022016574A (es) 2023-04-04

Family

ID=74043460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016574A MX2022016574A (es) 2020-06-29 2020-10-01 Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas.

Country Status (10)

Country Link
US (3) US10906944B2 (es)
EP (1) EP4171626A1 (es)
JP (1) JP2023533228A (es)
CN (2) CN112538105B (es)
AU (1) AU2020456732A1 (es)
BR (1) BR112022026733A2 (es)
CA (1) CA3188348A1 (es)
IL (1) IL299483A (es)
MX (1) MX2022016574A (es)
WO (1) WO2022005503A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210021530A (ko) * 2018-06-13 2021-02-26 더 스크립스 리서치 인스티튜트 신규한 구조적 컴포넌트들을 갖는 나노입자 백신들
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN116096732A (zh) 2020-01-31 2023-05-09 贝斯以色列护理医疗中心有限公司 用于预防和治疗冠状病毒感染的组合物和方法-sars-cov-2疫苗
BR112022016507A2 (pt) 2020-02-25 2022-11-22 Inovio Pharmaceuticals Inc Vacinas contra o coronavírus e métodos de uso
US20210260182A1 (en) * 2020-02-26 2021-08-26 Scott J. Goebel RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-CoV-2 VIRUS
EP4114458A4 (en) * 2020-03-05 2024-04-17 New York Blood Center Inc IMMUNOGENIC COMPOSITIONS AGAINST CORONAVIRUS-2 RESPONSIBLE FOR SEVERE ACUTE RESPIRATORY SYNDROME
KR102657261B1 (ko) * 2020-04-03 2024-04-15 조선대학교산학협력단 Ｃｏｖｉｄ－１９ 진단을 위한 재조합 코로나－１９ 바이러스 스파이크 단백질의 생산 및 이의 용도
WO2021211688A1 (en) * 2020-04-14 2021-10-21 Duke University Sars-2 spike protein designs, compositions and methods for their use
BR112022021259A2 (pt) * 2020-04-20 2022-12-27 Univ Indiana Trustees Rotavírus recombinante, composição imunogênica, métodos para induzir uma resposta imune protetora contra rotavírus e um coronavírus e para produzir um rotavírus recombinante, e, sistema de expressão de rotavírus recombinante
MX2022013254A (es) 2020-04-22 2023-01-24 BioNTech SE Vacuna contra el coronavirus.
CA3183086A1 (en) * 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
CN111732637B (zh) * 2020-05-25 2022-03-01 上海交通大学 抑制新型冠状病毒SARS-CoV-2感染宿主细胞的多肽及其应用
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
CA3187149A1 (en) * 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
JP2023535163A (ja) * 2020-07-15 2023-08-16 アンスティテュ・パストゥール Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法
WO2022167831A1 (en) * 2021-02-02 2022-08-11 Institut Pasteur Sars-cov-2 immunogenic compositions, vaccines, and methods
CN111848753B (zh) * 2020-07-20 2022-03-15 中国科学院过程工程研究所 新型冠状病毒抗原表位及其应用
WO2022089233A1 (zh) * 2020-10-30 2022-05-05 上海泽润生物科技有限公司 重组刺突蛋白及其制备方法和用途
WO2022150661A2 (en) * 2021-01-08 2022-07-14 The Regents Of The University Of California Monovalent and multivalent vaccines for prevention and treatment of disease
WO2022161495A1 (en) * 2021-01-29 2022-08-04 Genesail Biotech (shanghai) Co., Ltd. Recombinant sars-cov-2 vaccine
CA3206950A1 (en) * 2021-01-29 2022-08-04 Flowmetric Life Sciences, Inc. Detecting sars-cov-2 and other infective agents
CN112876542B (zh) * 2021-02-08 2021-10-29 暨南大学 一种新型冠状病毒t细胞的抗原表位肽及其应用
WO2022173940A1 (en) * 2021-02-10 2022-08-18 Duke University Coronavirus spike protein designs, compositions and methods for their use
WO2022174156A1 (en) * 2021-02-12 2022-08-18 Epivax, Inc. Prophylactic broad spectrum vaccine for sars-cov-2
EP4291212A1 (en) 2021-02-15 2023-12-20 LivingMed Biotech S.R.L. Genetically clostridium modifiedstrains expressing recombinant antigens and uses thereof
WO2022177990A2 (en) * 2021-02-17 2022-08-25 Emergent Product Development Gaithersburg Inc. Modified sars-cov-2 spike polypeptides and nanoparticles thereof
EP4294437A1 (en) * 2021-02-19 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Novel compositions of matter comprising stabilized coronavirus antigens and their use
CN114957409A (zh) * 2021-02-26 2022-08-30 中国科学院上海巴斯德研究所 基于s蛋白r815位点的冠状病毒干预的方法和产品
CN114456241B (zh) * 2021-03-01 2023-11-21 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
CN112691189A (zh) * 2021-03-01 2021-04-23 中国农业科学院北京畜牧兽医研究所 一种猫传染性腹膜炎病毒亚单位疫苗及应用
CN114369172A (zh) * 2021-03-01 2022-04-19 中国科学院微生物研究所 一种新型冠状病毒多价抗原、其制备方法和应用
CN113336857B (zh) * 2021-04-02 2023-01-31 深圳市众循精准医学研究院 一种新冠病毒亚单位疫苗及其构建方法
CN112979766B (zh) * 2021-04-16 2022-08-16 武汉大学 SARS-ConV-2病毒S蛋白膜外N端结构域高靶向性重组蛋白及其亚单位疫苗
AR125373A1 (es) * 2021-04-19 2023-07-12 Bharat Serums & Vaccines Ltd ANTICUERPOS POLICLONALES CONTRA SARS-CoV-2 Y SUS APLICACIONES
US20220339280A1 (en) * 2021-04-23 2022-10-27 Inovio Pharmaceuticals, Inc. Immunogenic Compositions Against SARS-COV-2 Variants and Their Methods of Use
WO2022234276A1 (en) * 2021-05-04 2022-11-10 SpyBiotech Limited Adenoviral vectors and vaccines thereof
CN113336838B (zh) * 2021-05-11 2022-05-17 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 新型冠状病毒肺炎重组痘苗病毒载体疫苗
CN113325177B (zh) * 2021-06-04 2024-03-01 博奥赛斯(重庆)生物科技有限公司 一种包含新型冠状病毒突变抗原的中和抗体检测试剂盒及其应用
CN113354717B (zh) * 2021-06-07 2022-04-08 扬州大学 一种新冠病毒SARS-CoV-2广谱多肽抗原及其特异性中和抗体和应用
EP4355761A1 (en) * 2021-06-14 2024-04-24 ModernaTX, Inc. Mrna vaccines encoding flexible coronavirus spike proteins
WO2022263451A1 (en) * 2021-06-15 2022-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes
EP4358999A1 (en) * 2021-06-23 2024-05-01 Consejo Superior De Investigaciones Científicas Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
EP4108257A1 (en) * 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
CN113249408B (zh) * 2021-06-23 2021-11-02 深圳湾实验室 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
EP4361170A1 (en) * 2021-06-24 2024-05-01 Yoshihiro Watanabe Antibody-inducing polypeptide and vaccine
CN113633762B (zh) * 2021-06-25 2023-10-13 中国矿业大学 一种介孔硅负载SARS-CoV-2 S蛋白B细胞抗原的纳米颗粒的制备方法及其应用
CN113588945A (zh) * 2021-06-30 2021-11-02 杭州迈尔德生物科技有限公司 一种基于化学发光的新型冠状病毒中和抗体检测试剂及试剂盒
CN113402591A (zh) * 2021-06-30 2021-09-17 李丁 基于棘突蛋白基因修饰干细胞的新型冠状病毒疫苗、其制备方法及应用
WO2023283106A1 (en) * 2021-07-07 2023-01-12 Codagenix Inc. Deoptimized sars-cov-2 variants and methods and uses thereof
WO2023003332A1 (ko) * 2021-07-19 2023-01-26 주식회사 바이오앱 식물 기반 covid-19 변이 재조합 스파이크 단백질 발현 벡터 및 상기 발현 벡터를 이용한 재조합 단백질
CN117295756A (zh) * 2021-07-23 2023-12-26 神州细胞工程有限公司 一种可诱导广谱中和活性重组多价新冠病毒三聚体蛋白疫苗的制备及应用
WO2023006062A1 (en) * 2021-07-30 2023-02-02 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for mutant coronavirus
CN113398260B (zh) * 2021-08-02 2021-12-24 深圳市华药康明生物药业有限责任公司 以痘苗病毒为载体的新冠疫苗
WO2023017536A1 (en) * 2021-08-12 2023-02-16 Reliance Life Sciences Pvt. Ltd. Immunogenic compositions for sars- cov-2
WO2023020623A1 (zh) * 2021-08-20 2023-02-23 百奥泰生物制药股份有限公司 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
CN113943375B (zh) * 2021-10-01 2022-08-16 中国科学院昆明动物研究所 一类来源于新型冠状病毒s2蛋白hr区域的重组融合蛋白及其应用
WO2023064907A1 (en) * 2021-10-15 2023-04-20 Yale University Compositions and methods for vaccination against pathogenic coronavirus species and variants
CN113943349A (zh) * 2021-10-22 2022-01-18 华瑞同康生物技术（深圳）有限公司 靶向识别抗新冠病毒中和抗体N-IgY-pAbs的核心氨基酸序列组及应用
WO2023081663A1 (en) * 2021-11-02 2023-05-11 Rush University Medical Center Methods of treating lung cancer and other cancers by recombinant sars-cov-2 spike s1
WO2023098842A1 (en) * 2021-12-03 2023-06-08 Suzhou Abogen Biosciences Co., Ltd. NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN
CN113862286B (zh) * 2021-12-03 2022-03-04 艾棣维欣(苏州)生物制药有限公司 编码sars-cov-2病毒c.37突变株抗原的dna分子、dna疫苗及应用
TW202338090A (zh) * 2021-12-17 2023-10-01 日商Ｖｌｐ醫療日本股份有限公司 高效疫苗
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2023142283A1 (zh) * 2022-01-27 2023-08-03 深圳市瑞吉生物科技有限公司 一种新型冠状病毒mRNA疫苗及其制备方法与应用
US11931410B1 (en) 2022-01-27 2024-03-19 Shenzhen Rhegen Biotechnology Co., Ltd. SARS-CoV-2 mRNA vaccine and preparation method and use thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024061188A1 (zh) * 2022-09-19 2024-03-28 百奥泰生物制药股份有限公司 一种冠状病毒多价疫苗及其应用
CN116769053B (zh) * 2023-05-26 2023-12-15 华中农业大学 重组AaLS-BPP融合肽、制备方法及应用
CN117723749A (zh) * 2024-02-07 2024-03-19 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050186575A1 (en) * 2001-05-17 2005-08-25 Rottier Petrus J.M. Corona-virus-like particles comprising functionally deleted genomes
WO2005002500A2 (en) * 2003-04-14 2005-01-13 Merck & Co., Inc. Inhibitors of coronavirus
CN1223605C (zh) * 2003-05-16 2005-10-19 中国科学院微生物研究所 抑制sars冠状病毒的多肽药物及其衍生物和其应用
CN1852921A (zh) * 2003-07-21 2006-10-25 美国政府卫生及公众服务部国家卫生协会 Sars冠状病毒刺突糖蛋白的可溶性片段
EP1701977A2 (en) * 2003-12-10 2006-09-20 Agency for Science, Technology and Research Sars coronavirus s proteins and uses thereof
WO2005117960A1 (fr) * 2004-06-04 2005-12-15 Cancer Center Sun Yat-Sen University Vaccin adn contre le sras et procede de preparation de celui-ci, utilisation de gene glycoproteine spicule (spike) des coronavirus pour vaccin
EP3189067B1 (en) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant hiv-1 envelope proteins and their use
WO2017192434A1 (en) 2016-05-02 2017-11-09 The Scripps Research Institute Compositions and methods related to hiv-1 immunogens
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN111542534B (zh) 2017-11-01 2024-04-30 斯克利普斯研究院 新型支架式hiv-1疫苗免疫原
KR20210021530A (ko) 2018-06-13 2021-02-26 더 스크립스 리서치 인스티튜트 신규한 구조적 컴포넌트들을 갖는 나노입자 백신들
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Also Published As

Publication number Publication date
CN112538105B (zh) 2022-04-12
US20210139543A1 (en) 2021-05-13
CN112300253A (zh) 2021-02-02
US20200407402A1 (en) 2020-12-31
EP4171626A1 (en) 2023-05-03
US10906944B2 (en) 2021-02-02
CA3188348A1 (en) 2022-01-06
IL299483A (en) 2023-02-01
WO2022005503A1 (en) 2022-01-06
JP2023533228A (ja) 2023-08-02
BR112022026733A2 (pt) 2023-01-24
CN112538105A (zh) 2021-03-23
US11845777B2 (en) 2023-12-19
US20240140993A1 (en) 2024-05-02
AU2020456732A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2022016574A (es) Inmunógenos de proteína de espicula (s) de coronavirus estabilizados y vacunas relacionadas.
MX2022009460A (es) Vacuna contra el coronavirus.
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
MX2022015132A (es) Vacunas combinadas a base de acidos nucleicos.
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2019001920A (es) Arn la terapia contra el cancer.
WO2018115527A3 (en) Mers coronavirus vaccine
MX2018009917A (es) Vacuna contra el virus del zika.
MX2022015040A (es) Proteina espicular (s) del coronavirus geneticamente manipulada y metodos de uso de la misma.
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
CY1109463T1 (el) Πεπτιδια kdr και εμβολια που τα περιλαμβανουν
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PT1286671E (pt) Composicoes para o tratamento de cancro colorrectalque compreendem talidomida e irinotecan
MX2023001877A (es) Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9.
MX2022014387A (es) Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva).
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
MX2022014161A (es) Vacunas contra sars-cov-2.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
WO2022103929A3 (en) Nucleic acids, proteins, and vaccines of sars-cov-2
MX2020013601A (es) Receptores de las celulas t especificos de cancer.